Search alternatives:
marked decrease » marked increase (Expand Search)
large decrease » larger decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
marked decrease » marked increase (Expand Search)
large decrease » larger decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1
Development of Selective and Soluble Mitochondrial Complex 1 Inhibitors Derived from Papaverine for Radiosensitization of Cancer
Published 2025“…We have therefore generated additional derivatives which have improved mitochondrial complex 1 inhibition and reduced PDE10A inhibition. …”
-
2
Development of Selective and Soluble Mitochondrial Complex 1 Inhibitors Derived from Papaverine for Radiosensitization of Cancer
Published 2025“…We have therefore generated additional derivatives which have improved mitochondrial complex 1 inhibition and reduced PDE10A inhibition. …”
-
3
-
4
-
5
-
6
-
7
-
8
-
9
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
-
10
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
-
11
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
-
12
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
-
13
Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer
Published 2024“…Mechanistically, compound <b>E35</b> markedly decreased the expression of Skp2, as well as increased the expression of its substrates p21 and p27. …”
-
14
-
15
Conformational Role of Methyl in the Potency of Cyclohexane-Substituted Squaramide CCR6 Antagonists
Published 2025“…Herein we report the design of a potent CCR6 antagonist capable of inhibiting the chemotactic migration of CCR6<sup>+</sup> T cells in vitro. …”
-
16
Conformational Role of Methyl in the Potency of Cyclohexane-Substituted Squaramide CCR6 Antagonists
Published 2025“…Herein we report the design of a potent CCR6 antagonist capable of inhibiting the chemotactic migration of CCR6<sup>+</sup> T cells in vitro. …”
-
17
Conformational Role of Methyl in the Potency of Cyclohexane-Substituted Squaramide CCR6 Antagonists
Published 2025“…Herein we report the design of a potent CCR6 antagonist capable of inhibiting the chemotactic migration of CCR6<sup>+</sup> T cells in vitro. …”
-
18
-
19
-
20